(UroToday.com) In this presentation, Dr. Mark Markowski discussed results of a Phase 1b/2 study of sabizabulin (VERU-111), an androgen receptor transport disruptor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent (ARTA). Sabizabulin is an oral agent that inhibits microtubule assembly as well as disrupts androgen receptor transport from the cytoplasm to the nucleus.